Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen presents NESP, SD/01 and KGF data

Data from a Phase II open label dose escalation and pharmacokinetics trial showed that AMGN's novel erythropoiesis stimulating protein (NESP) had a 50 hour

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE